The trial program will be led by interventional cardiologist Ryan Kaple, MD, who joined the Hackensack team in May, according to a Dec. 15 news release from the health system.
The center now uses the SafeCross septal puncture and access system, which allows access to the left chamber of the heart more safely and accurately, the release said.
The first clinical study aims to determine the effectiveness of a minimally invasive device that treats functional tricuspid regurgitation. Hackensack is one of only four medical centers in the U.S. participating in the trial.
The second clinical study will evaluate the effectiveness of an AccuCinch Ventricular Restoration System in patients experiencing heart failure, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
